[Contribution to the clinical study of a new neuroleptic: sulpiride].
D000275:Adjustment Disorders / Q000188:drug therapy; D000639:Amitriptyline / Q000627:therapeutic use; D000856:Anorexia Nervosa / Q000188:drug therapy; D000928:Antidepressive Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy; D006212:Hallucinations / Q000188:drug therapy; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D010259:Paranoid Disorders / Q000188:drug therapy; D010554:Personality Disorders / Q000188:drug therapy; D010698:Phobic Disorders / Q000188:drug therapy; D011618:Psychotic Disorders / Q000188:drug therapy*; D011759:Pyrrolidines / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012893:Sleep Wake Disorders / Q000139:chemically induced; D019966:Substance-Related Disorders / Q000188:drug therapy; D013451:Sulfonic Acids / Q000627:therapeutic use*; D014149:Tranquilizing Agents / Q000008:administration & dosage* / Q000009:adverse effects
D000928:Antidepressive Agents; D011759:Pyrrolidines; D013451:Sulfonic Acids; D014149:Tranquilizing Agents; D000639:Amitriptyline
Contribution à l'étude clinique d'un nouveau neuroleptique: le sulpiride.